Rgenta completes $20 million seed round financing

recently completed a $20 million seed round financing for Regenta Therapeutics( "Rgenta"). The financing was jointly led by Boehringer Ingelheim Venture Fund, Ewai China, Kaitai Capital and Lenovo Star. Rgenta builds a unique RNA-related target discovery and screening platform dedicated to targeted RNA drug development for disease-related targets to address clinically unsealed needs.

, the company has several projects are advancing preclinical research, including clinically unsophiced tumors, rare diseases and other fields.


Rgenta's founding team has world-class research and development and industry experience in targeted RNA drug development Rgenta's luxurious founding team consists of world-class computational biologists, genomicists and pharmaceutical chemists with deep experience in both research and industry.The founder, Dr. Yu Hualin, has nearly 20 years of research and development and management experience in major international pharmaceutical companies and is currently serving full-time as CEO of Regenta. Dr. Yan holds a Ph.D. in Bioinsynurance from Boston University in the United States, has extensive research and development experience in computational biology and genomics in both industry and academia, and has served as An Associate Professor at the University of Massachusetts School of Medicine, Visiting Professor at Brandis University, Senior Chief Scientist at Pfizer, Research and Group Leader, AbbVie Communications Biology and Genomics Head, and has extensive leadership in all aspects of preclinical drug development, including target validation, drug discovery, and has been responsible for and led projects in the areas of cancer and neuronomics. In addition, Dr. Yan is the PI of the GTEx Genome Project.Co-founder Dr. Ong Zhiping is a tenured professor at the University of Massachusetts Medical Center, and Professor Ong has made outstanding research achievements in computational biology, genomics, oscic genomics, and RNA regulation. In addition, Professor Ong co-led two international genome project ENCODE and psychENCODE data analysis centers.Co-founder Dr. Travis Wager has more than 20 years of experience in drug development at Pfizer, where he has experience in rare diseases, cardiovascular diseases, and neurological disorders, successfully advancing eight drug molecules into clinical practice. Dr. Travis Wager also has entrepreneurial experience, has served as Vice President of Aquinnah Pharmaceuticals, and currently dr. Travis Wager is a full-time member of Regenta's CSO.In addition to a strong founding team, the company has also formed a distinguished scientific advisory board in genomics and RNA biology, including Dr. Phillip Zamore, Chairman of the Institute of RNA Therapy at the University of Massachusetts School of Medicine and Professor of Biomedical Sciences at Gretchen Stone Cook, co-founders of two biotech companies, Allylam Pharmaceuticals and Voyager Therapeutics; Dr. Friedrich Metzger, CEO of Versameb and former head of Roche's Rare Diseases, led the development of Risdiplam, a small molecule RNA shear modifier used to treat spinal muscular dystrophy.With a world-class team, Rgenta hopes to develop targeted RNA drugs for targets that are highly relevant to disease but cannot be drugized in traditional ways.

RNA-targeted drugs bring new changes to drug development, Rgenta has built an innovative and unique technology platformFor small molecule therapies, the vast majority of their targets are proteins. There are about 20,000 proteins translated into the human genome, of which disease-related proteins account for about 10%-15% (2000-3000), but so far, fewer than 700 protein targets have been approved, and many proteins are not "pharmacological", which means that it is difficult to inhibit their development of small molecules, these targets currently lack effective interventions, but there is great development value and potential. In addition, only 1.5% of the human genome is trinated as related proteins, and about 70% of the remaining parts are transcoded as non-coding RNA. Drug development targeting RNA can regulate gene expression with great potential and opportunities.
Rgenta is committed to drug development that address the "drug-insisting" targets of traditional methods, which are often located in key regulatory procedures and signaling paths for disease development and are ideal targets for drug intervention. To this end, Rgenta has built a unique RNA-related target detection and compound screening technology platform. The platform uses a large amount of genomic data and advanced algorithms to identify RNA targets that can be selectively acted upon by small molecules, and uses efficient targeted RNA assays to quickly screen and optimize functional lead compound molecules. The function of RNA is regulated by small molecule drugs, which solves the problem of "non-drugable" traditional proteins."We are very pleased to be working with professional funds in the field of biomedicine to complete this seed round of financing," said Dr. Yu Hualin, founder and CEO of the company. With their support, we can quickly advance existing targeted RNA programs to preclinical research. In the future, we will find more high-value RNA targets in different therapeutic areas, further enrich the company's pipeline, and address many of the disease treatment dilemmas faced by traditional pathways by regulating RNA capabilities, alleviating the pain of clinical patients. Dr

co-founder of CSO Travis Wager, said: "Rgenta's RNA targeting platform provides an innovative way to reach previously uncancered targets that are highly relevant to disease. The key to the success of our platform is that we can analyze large amounts of genomic data and identify regulatory places in RNA that can be effectively and selectively regulated by small molecules. Our unique technology platform allows us to quickly screen small molecules for action on different RNA targets, regulating protein production or changing protein function. The
(arterial network)